HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65

Benzinga Newsdesk www.benzinga.com Neutral 49.9%

Neg 0% Neu 49.9% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $70 to $65.